Download our NEW Mobile App!
Holbrook Drugs Logo

Get Healthy!

U.S. Death Rate From Alcoholic Liver Cirrhosis Triples Over Two Decades
  • Posted June 20, 2022

U.S. Death Rate From Alcoholic Liver Cirrhosis Triples Over Two Decades

Americans may have a collective drinking problem, made worse by the obesity epidemic, new research suggests. The new study found that deaths from alcoholic cirrhosis have more than tripled in 20 years.

In 1999, alcoholic cirrhosis -- an advanced form of alcohol-related liver disease -- killed just over 6,000 Americans (a rate of 3 per 100,000). By 2019, deaths from the condition had soared to nearly 24,000 (a rate of 11 per 100,000).

"The hypothesis is that people are drinking more and starting earlier in life," said lead researcher Dr. Charles Hennekens, the First Sir Richard Doll Professor & Senior Academic Adviser to the Dean at the Charles E. Schmidt College of Medicine at Florida Atlantic University in Boca Raton.

But there may be other factors at work, Hennekens added, including a dramatic increase in obesity, along with more sedentary lifestyles.

"That leads to fatty liver," Hennekens said. "The same kind of thing that alcohol does. My hypothesis is that the reason we're seeing more of liver disease earlier is not just that people are drinking more, but that they're eating more and exercising less, so the damage to the liver is accelerating."

Obesity and lack of exercise are also at the root of the epidemic of diabetes, as well as heart disease, stroke and some cancers. "The risk factors are the same," he noted.

Hennekens said that as far as drinking goes, people should limit the amount of alcohol they drink to no more than two drinks a day for men and no more than one for women.

Doctors should counsel their patients that those who consume lots of alcohol have the highest death rates from both cirrhosis and heart disease, he added.

Alcoholic cirrhosis accounts for one-third of all liver transplants in the United States, the study authors noted.

"While the data indicate that those who have one to two drinks daily have lower risks of cardiovascular disease than nondrinkers, it is also true that the difference between drinking smaller and larger amounts of alcohol means the difference between preventing and causing premature death," Hennekens said.

For the study, Hennekens and his colleagues used data from the U.S. Centers for Disease Control and Prevention to look at trends in death from alcoholic cirrhosis from 1999 to 2019.

The investigators found that during those two decades there were statistically significant increases in deaths from alcoholic cirrhosis in every age group from 25 and up. The largest increase was sevenfold among those aged 24 to 35 and the steepest increase was seen among those aged 65 to 74.

The report was published online recently the American Journal of Medicine.

Dr. Tiffany Wu, a gastroenterologist at the Mayo Clinic in Rochester, Minn., said that alcohol-associated liver disease is one of the leading causes of liver-related deaths in the United States.

"The rising prevalence of high-risk drinking and alcohol use disorder has fueled these trends in the development of chronic liver disease and its complications," she said. "Although effective treatments are available for alcohol use disorder, they are currently underutilized."

Barriers to care include other medical conditions, the stigma around addiction and limited access to care, Wu said.

"Existing care delivery models have been further restricted due to challenges related to the pandemic," she said. "Thus, there is an urgent need to improve methods of identifying individuals with high risk for developing disease, and also to utilize novel digital platforms and technology to personalize treatment and prevention."

More information

For more on liver disease, head to the U.S. National Institute of Diabetes and Digestive and Kidney Diseases.

SOURCES: Charles Hennekens, MD, DrPH, First Sir Richard Doll Professor & Senior Academic Adviser to the Dean, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton; Tiffany Wu, MD, gastroenterologist, Mayo Clinic, Rochester, Minn.; American Journal of Medicine, May 27, 2022, online

HealthDay
Health News is provided as a service to Holbrook Drugs site users by HealthDay. Holbrook Drugs nor its employees, agents, or contractors, review, control, or take responsibility for the content of these articles. Please seek medical advice directly from your pharmacist or physician.
Copyright © 2024 HealthDay All Rights Reserved.